Nautilus Biotechnology Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $0.2 million, primarily from grant revenue related to the Michael J. Fox Foundation-funded alpha-synuclein proteoform assay.

Operating Expenses: $15.9 million, down approximately 7% year-over-year.

R&D Expenses: $9.6 million, down 8% due to lower laboratory spending and stock-based compensation.

SG&A Expenses: $6.3 million, down 6% due to reduced salaries and benefits.

Net Loss: $14.5 million or $0.11 per share, compared to a net loss of $15 million or $0.12 per share in the prior year.

Cash Position: $129.2 million at the end of Q2, down from $143.4 million at the end of Q1, providing a cash runway into Q1 2028.

2Strategic Updates and Business Highlights

Shift in R&D Focus: Nautilus is reallocating resources from broad-scale applications to proteoform applications due to growing customer demand and momentum in the scientific community.

Proteoform Development: The company has seen strong interest in its proteoform assays, including successful collaborations with institutions like the Allen Institute and the Buck Institute for Aging.

New Assays: The company is prioritizing the development of proteoform assays, including AKT1 for oncology, with plans for early access in late 2026 and general availability in mid-2027.

Commercial Organization: The sales team has expanded to three members, with positive feedback from customers regarding the unique capabilities of Nautilus's platform.

3Forward Guidance and Outlook

Revenue Guidance: Maintaining a full-year revenue guidance of approximately $0.5 million, primarily from grant funding and early access program services.

Commercialization Timeline: The company expects to open the Voyager platform for pre-orders in early 2027, with shipments beginning mid-2027.

Assay Development: Anticipating a rapid increase in the number of proteoform assays, aiming for around 20 by mid-2028.

4Bad News, Challenges, or Points of Concern

Broad-scale Application Delay: The broad proteome application is behind schedule, with no general availability expected in 2027 due to insufficient assay performance.

Market Conditions: There is some uncertainty in the academic market, with funding being somewhat choppy, although improving.

Revenue Generation: The current revenue is minimal, and the transition from early access projects to significant revenue-generating contracts may take time.

5Notable Q&A Insights

Sales Strategy: Management emphasized the importance of aligning the size of the sales team with the serviceable market opportunity, indicating no immediate plans for expansion but potential growth next year.

Unique Value Proposition: The proteoform platform is positioned as the only one capable of measuring proteoforms at scale, which is expected to drive customer interest and engagement.

Customer Funding: Conversations with biopharma customers indicate stable budgets, while academic funding is improving but still presents challenges.

Future Revenue Potential: Management refrained from specifying customer acquisition numbers but expressed optimism about the commercial opportunity, particularly with the upcoming AKT1 assay. Overall, Nautilus is strategically pivoting towards proteoform applications, which are generating positive customer feedback, while facing challenges in broad-scale application timelines and revenue generation.